v3.26.3
Share Capital (Tables) - Chemomab Therapeutics Ltd [Member]
 6 Months Ended 12 Months Ended
Jun. 30, 2026
Dec. 31, 2025
Schedule of the Effect of Share-based Compensation on the Statements of Operations

 

   Six Months ended   Three Months ended   Six Months ended   Three Months ended 
   June 30, 2026   June 30, 2026   June 30, 2025   June 30, 2025 
   USD thousands   USD thousands   USD thousands   USD thousands 
Research and development   79    37    22    (39)
General and administrative   142    50    223    118 
                     
Total share-based compensation expenses   221    87    245    79 

 

   Year ended   Year ended   Year ended 
   December 31,   December 31,   December 31, 
   2025   2024   2023 
   USD thousands   USD thousands   USD thousands 
Research and development   158    401    407 
General and administrative   465    216    1,084 
                
Total share-based compensation expenses   623    617    1,491 
Schedule of Number and Weighted Average Exercise Prices of Option

 

  

Weighted

average

exercise price

  

Number

of options

  

Weighted

average

remaining contractual

life (in years)

 
   June 30, 2026   June 30, 2026   June 30, 2026 
Outstanding at January 1, 2026   0.14    31,492,720    6.71 
Forfeited   0.17    (1,418,880)     
Granted   0.03    1,930,960    9.79 
                
Outstanding at June 30, 2026   0.13    32,004,800    6.14 

 

  

Weighted average

exercise price

  

Number

of options

  

Weighted

average

remaining contractual life (in years)

  

Weighted

average

exercise price

  

Number

of options

  

Weighted

average

remaining contractual life (in years)

 
   2024   2024   2024   2023   2023   2023 
Outstanding at January 1   0.16    29,873,100    5.99    0.33    35,191,540    7.42 
Exercised   -    -    -    -    -    - 
Forfeited   0.19    (667,820)   -    0.39    (20,373,620)   - 
Granted   0.03    2,845,020    8.56    0.07    15,055,180    5.86 
                               
Outstanding at December 31   0.15    32,050,300    7.34    0.16    29,873,100    5.99 

 

  

Weighted average

exercise price

  

Number

of options

  

Weighted

average

remaining contractual life (in years)

  

Weighted

average

exercise price

  

Number

of options

  

Weighted

average

remaining contractual life (in years)

 
   2025   2025   2025   2024   2024   2024 
Outstanding at January 1   0.15    32,050,300    7.34    0.16    29,873,100    5.99 
Exercised   0.03    (449,920)   -    -    -    - 
Forfeited   0.11    (4,869,540)   -    0.19    (667,820)   - 
Granted   0.06    4,761,880    9.30    0.03    2,845,020    8.56 
                               
Outstanding at December 31   0.14    31,492,720    6.71    0.15    32,050,300    7.34 
Schedule of Unvested RSA
   Number of RSAs 
RSA  June 30, 2026 
Unvested at beginning of the year   10,071,360 
Granted   - 
Issuance of ordinary shares upon vesting of RSAs   (1,486,480)
Forfeited   - 
      
Outstanding at June 30, 2026   8,584,880 

 

   Number of RSAs 
RSA  2025 
Unvested at beginning of the year   6,443,900 
Granted   5,870,980 
Vested   (1,433,120)
Forfeited   (810,400)
      
Outstanding at December 31, 2025   10,071,360 
Schedule of Assumptions Used to Calculate the Fair Value of the Options  

 

   2025 grants of Options 
Weighted average share price (in U.S. dollar)(a)   0.05 
Exercise price (in U.S. dollar)   0.06-0.08 
Expected life of options (in years)(b)   5.44-5.5 
Expected volatility(c)   96%-105.2%
Risk-free interest rate(d)   4.09%-4.19%
Dividend yield   0%

 

  (a) The weighted average share price is based on the Company’s Ordinary Share closing price on the stock exchange as at the grant date
     
  (b) Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions.
     
  (c) Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company’s trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company’s industry that the Company considers to be comparable to its own business over a period equivalent to the option’s expected term.
     
  (d) The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.